Monopar Therapeutics Inc (MNPR)

In the past six months, Monopar Therapeutics' stock price has fluctuated, reaching $53.37 per share as of May 1, 2026, an 18.71% increase from May 2, 2025. Key events include Q3 2025 financial results and program updates, Q4 and full-year 2025 financial results and business update, a public offering in 2025, presentations at medical meetings, and insider trading.

There is no indication of significant demand seasonality for Monopar Therapeutics' products and services. Demand is likely driven by patient need and medical necessity rather than seasonal fluctuations.

Monopar Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs in oncology and rare diseases. Their pipeline includes ALXN1840 for Wilson Disease, MNPR-101 radiopharmaceutical programs targeting uPAR for various cancers, Camsirubicin for soft tissue sarcoma, and MNPR-202 for drug-resistant cancers. The company builds its pipeline through in-house efforts and licensing or acquiring late preclinical and clinical-stage therapeutics.

Monopar Therapeutics Inc. is headquartered in Wilmette, Illinois, United States, and is developing therapeutics for cancer treatment in the United States. Its MNPR-101 radiopharmaceutical programs have ongoing Phase 1 clinical activity in Australia.

Monopar Therapeutics' brand reputation has been positively influenced by positive clinical data and presentations, publications in peer-reviewed journals, the strategic leadership appointment of Susan Rodriguez, and regulatory progress.

Monopar Therapeutics Inc. is primarily owned by institutional shareholders and insiders. Institutional shareholders own 82.52% of the company, while insiders own 284.24%. Arthur J. Klausner is the largest individual shareholder, owning 137.10% of the company, and Michael J. Brown holds 71.81% of the company.